<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131243">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063477</url>
  </required_header>
  <id_info>
    <org_study_id>Oligo_extract</org_study_id>
    <nct_id>NCT02063477</nct_id>
  </id_info>
  <brief_title>Effect of Oligopin® on Blood Pressure.</brief_title>
  <official_title>Effect of a French Maritim Pine Bark Extract Oligopin® on Blood Pressure: Double Blind, Crossover, Placebo-controlled Nutrition Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technological Centre of Nutrition and Health, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technological Centre of Nutrition and Health, Spain</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of consumption of a food supplement
      rich in procyanidins extracted from the bark of French pine, Oligopin®, on blood pressure of
      people with mild / moderate degree of hypertension. Furthermore, the effect Oligopin®
      consumption on markers involved in the development of hypertension, and endothelial function
      in key enzymes that regulate blood pressure, inflammation and oxidation are considered.
      Also, try to advance the understanding of the molecular mechanisms that regulate blood
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Differences detected on the time evolution of BP  both in two arms of intervention</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthropometric data (Weight, BMI, Waist circumference)</measure>
    <time_frame>weeks 2, 5, 6, 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function (Laser-Doppler)</measure>
    <time_frame>Weeks 2, 5, 6, 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry for on-going study control (Glucose, Total cholesterol levels, Creatinine, Albumine, Transaminases (GPT, GOT)</measure>
    <time_frame>Week 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Biomarkers related with endothelial function (Endotheline-1, Nitrites (NO3), Nitrates (NO2)) - Biomarker related with blood pressure homeostasis (ACE activity)</measure>
    <time_frame>Weeks 2, 5, 6, 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Biomarker related with inflammatory processes (High sensitive C Reactive Protein) - Biomarkers of  antioxidant system (Oxidised- LDL levels, Reduced glutathione, Oxidised glutathione, Ratio Glutathione balance)</measure>
    <time_frame>Weeks 2, 5, 6, 9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Product one</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule</description>
    <arm_group_label>Product one</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oligopin®</intervention_name>
    <description>Oligopin® PUR' expert (%)  is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:
- TOTAL POLYPHENOL CONTENT &gt; 96
MONOMERS + PHENOLIC ACIDS 30
DIMERS                                        &gt;15
OTHER OLIGOMERS                          50
PROCYANIDINS CONTENT (GPC) &gt; 67
The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine  + 30 mg magnesium stearate: total weight: 280 mg/gelule</description>
    <arm_group_label>Product two</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  early stages of hypertension (systolic BP ≥ 140 and ≤ 159 mm Hg) and/or diastolic BP:
             ≥ 90 and ≤ 99 mm Hg

          -  not receiving BP-lowering medication.

          -  obtained written informed consent before the initial screening visit.

        Exclusion Criteria:

          -  Body Mass Index (BMI) &gt; 30 kg/m2

          -  taking antihypertensive medications

          -  smoking

          -  pregnant or who intends to become pregnant

          -  wife in breastfeeding period

          -  persons with a self-reported history of clinical cardiovascular disease, cancer,
             chronic kidney disease (or a serum creatinine ≥ 1.7 mg/dL for men and ≥ 1.5 mg/dL for
             women)  hypercholesterolemia (LDL-c ≤ 189 mg/dL, diabetes mellitus (or serum glucose
             ≥126 mg/dL), or consumption of more than 14 drinks of alcoholic beverages per week.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa M VALLS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universitat Rovira i Virgili</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa SOLÀ, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Sant Joan, Universitat Rovira i Virgili, CTNS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosa Solà, PhD</last_name>
    <phone>977759300</phone>
    <phone_ext>9369</phone_ext>
    <email>rosa.sola@urv.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Technological Center of Nutrition and Health (CTNS)</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesc Puiggròs, Dr.</last_name>
      <phone>977751382</phone>
      <email>francesc.puiggros@ctns.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
